Table 1. Patient characteristics and... | American Society of Hematology

Table 1.

Patient characteristics and outcomes

					GVHD			HTLV-1 proviral load
UPN	Age, y/sex	ATL subtype	Donor HTLV-1 antibody	Complete chimerism, PB MNCs, > 90% of donor cells, d	Acute	Chronic	Before RIST	After RIST, lowest level	Outcome	Survival, d
1	67/F	Acute	+	No	0	NE	292	68	LN relapse, d 47, DOD	135
2	61/F	Acute	-	14	IV	No	> 1000	2	LN relapse, d 47, CR after d/c CsA, died of aGVHD	173
3	62/F	Lymphoma	+	28	0	NE	30	43	LN relapse, d 14, DOD	43
4	62/M	Acute	+	14	1	Yes	> 1000	< 0.5	LN and skin relapse, d 28 and CR after d/c CsA	> 1214
5	51/M	Acute	-	42	0	No	709	223	LN and skin relapse, d 21, PR after d/c CsA, DOD	173
6	66/F	Acute	+	14	II	Yes	798	7	CR	> 1177
7	51/M	Acute	-	14	II	Yes	27	< 0.5	CR	> 1162
8	55/F	Lymphoma	+	20	0	No	331	67	LN relapse, d 74, DOD	201
9	53/M	Lymphoma	-	17	II	Yes	236	< 0.5	CR	> 1017
10	54/M	Lymphoma	-	17	II	Yes	440	< 0.5	LN relapse, d 171, CR after chemoradiotherapy	> 910
11	55/M	Acute	+	21	NE	NE	214	NE	NE	NE
12	66/F	Acute	-	14	0	Yes	> 1000	< 0.5	Died of cGVHD and infection	285
13	57/M	Acute	+	15	III	No	> 1000	2	LN and lung relapse, d 182, DOD	266
14	67/F	Lymphoma	-	15	III	No	582	< 0.5	LN relapse, d 62, DOD	219
15	54/M	Acute	+	28	III	NE	> 1000	< 0.5	Died of aGVHD and sepsis	71
16	56/M	Acute	-	14	IV	No	> 1000	< 0.5	Died of aGVHD	126

					GVHD			HTLV-1 proviral load
UPN	Age, y/sex	ATL subtype	Donor HTLV-1 antibody	Complete chimerism, PB MNCs, > 90% of donor cells, d	Acute	Chronic	Before RIST	After RIST, lowest level	Outcome	Survival, d
1	67/F	Acute	+	No	0	NE	292	68	LN relapse, d 47, DOD	135
2	61/F	Acute	-	14	IV	No	> 1000	2	LN relapse, d 47, CR after d/c CsA, died of aGVHD	173
3	62/F	Lymphoma	+	28	0	NE	30	43	LN relapse, d 14, DOD	43
4	62/M	Acute	+	14	1	Yes	> 1000	< 0.5	LN and skin relapse, d 28 and CR after d/c CsA	> 1214
5	51/M	Acute	-	42	0	No	709	223	LN and skin relapse, d 21, PR after d/c CsA, DOD	173
6	66/F	Acute	+	14	II	Yes	798	7	CR	> 1177
7	51/M	Acute	-	14	II	Yes	27	< 0.5	CR	> 1162
8	55/F	Lymphoma	+	20	0	No	331	67	LN relapse, d 74, DOD	201
9	53/M	Lymphoma	-	17	II	Yes	236	< 0.5	CR	> 1017
10	54/M	Lymphoma	-	17	II	Yes	440	< 0.5	LN relapse, d 171, CR after chemoradiotherapy	> 910
11	55/M	Acute	+	21	NE	NE	214	NE	NE	NE
12	66/F	Acute	-	14	0	Yes	> 1000	< 0.5	Died of cGVHD and infection	285
13	57/M	Acute	+	15	III	No	> 1000	2	LN and lung relapse, d 182, DOD	266
14	67/F	Lymphoma	-	15	III	No	582	< 0.5	LN relapse, d 62, DOD	219
15	54/M	Acute	+	28	III	NE	> 1000	< 0.5	Died of aGVHD and sepsis	71
16	56/M	Acute	-	14	IV	No	> 1000	< 0.5	Died of aGVHD	126